KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.

Hong-Fei Gao, Guo-Lin Ye, Ying Lin, Qin Huang, Jie Dong, Yin Cao, Yan-Xia Zhao, Qian-Jun Chen, Shi-Hui Ma, Jie Ouyang, Jin-Hui Ye, Hua-Wei Yang, Yuan-Qi Zhang, Yong-Cheng Zhang, Gang-Ling Zhang, Wei Li, Yunjian Zhang, Zhi-Yong Wu, Ying-Yi Lin, Teng Zhu, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Hao Peng, Bo Chen, Yi-Tian Chen, Fei Ji, Min-Yi Cheng, Jie-Qing Li, Zefei Jiang, Kun Wang

J Clin Oncol 44(17) 1587-1596

PMID41576297
PMCIDPMC13258097
DOI10.1200/JCO-25-02176
发表日期2026-01-23
入排依据:The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it is ineligible because the primary efficacy endpoint is pathologic complete response (pCR), which is a binary outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). No time-to-event analysis, Kaplan-Meier, or hazard ratio for efficacy is indicated in the abstract.
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:AI 判定为 other;FIG 3.:森林图/亚组分析图。
摘要

摘要

PURPOSE: The neoCARHP aimed to investigate the efficacy and safety of investigator-selected taxane (docetaxel, paclitaxel, or nab-paclitaxel) plus trastuzumab and pertuzumab, with carboplatin (TCbHP) or without carboplatin (THP), in stage II and III human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHODS: The neoCARHP was a multicenter, randomized, phase III, noninferiority study. Eligible patients were women age 18 years or older with previously untreated, stage II and III, HER2-positive invasive breast cancer. Patients were randomly assigned (1:1) to receive six 3-week cycles of TCbHP or THP. The primary end point was pathologic complete response (pCR) rate in the breast and axilla (ypT0/is ypN0) in the modified intention-to-treat (mITT) population (all randomly assigned patients receiving at least one dose of study treatment). Safety was evaluated in all patients who received any study treatment. RESULTS: Between April 30, 2021, and August 27, 2024, 774 patients were randomly assigned and 766 were included in the mITT population (382 in THP and 384 in TCbHP). pCR was achieved in 245 (64.1% [95% CI, 59.1 to 69.0]) patients in the THP group and 253 (65.9% [60.9-70.6]) in the TCbHP group (absolute difference, -1.8% [95% CI, -8.5 to 5.0]; odds ratio, 0.93 [95% CI, 0.69 to 1.25]; Pnoninferiority = .0089). The THP group had fewer grade 3 and 4 adverse events (20.7% v 34.6%) and serious adverse events (1.3% v 4.7%) than the TCbHP group. The most common grade 3 and 4 adverse events with THP were neutropenia (6.8% v 16.4% with TCbHP), leukopenia (5.5% v 14.8%), and diarrhea (2.6% v 4.2%). No treatment-associated deaths occurred. CONCLUSION: THP provided noninferior pCR rates and improved tolerability compared with TCbHP. Omitting carboplatin may be applicable in HER2-positive breast cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram. HER2, human epidermal growth factor receptor 2; ITT, intention-to-treat.
非 KM Figure
FIG 2.FIG 2. pCRs grouped by treatment arms. (A) pCRs in the mITT population. (B) pCRs stratified by HR status. ER, estrogen receptor; HR, hormone receptor; mITT, modified intention-to-treat; OR, odds ratio; pCR, pathologic complete response; PR, progesterone receptor.
非 KM Figure
FIG 3.FIG 3. Subgroup analyses of pCR. Nodal status and HR status were prespecified stratification factors. All other subgroup analyses were post hoc. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; ISH, in situ hybridization; pCR, pathologic complete response; PR, progesterone receptor; TCbHP, taxane, carboplatin, trastuzumab, and pertuzumab; THP, taxane, trastuzumab, and pertuzumab.
非 KM Figure